+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 122 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.

Age: 18Years +All GendersPhase 1Phase 2
54 locations
S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a once-daily oral medication called AP1189, at a dose of 100 mg, compared to a placebo in participants who have respiratory insufficiency expected to be caused by respiratory viral infections such as SARS-CoV-2, Influenza A or B, or RSV. This study is a Phase 2, randomized, double-blind, placebo-controlled trial aiming to include 96 hospitalized participants. The goal is to assess AP1189 as an add-on treatment to the standard care provided for these respiratory infections. Participants will be randomly assigned in equal numbers to receive either AP1189 tablets or matching placebo tablets once daily for 14 days, alongside their standard of care treatment. The study monitors participants during this 14-day treatment period to evaluate treatment outcomes and safety. During the study, participants will be assessed for a composite outcome including death, need for invasive mechanical ventilation or ECMO, cardiovascular organ support, or new renal failure within 28 days. The study includes clinical evaluations, oxygen saturation measurements, and safety monitoring during and after treatment. Overall participation lasts at least 28 days to capture these outcomes and monitor participant health.

Age: 18Years +All GendersPhase 2
11 locations
P

Actively Recruiting

Researchers are evaluating ARO-ALK7, a drug given by injection, in adult participants with obesity, both with and without Type 2 Diabetes Mellitus T2DM. This Phase 12a study aims to understand the safety, tolerability, how the body processes the drug, and how the drug affects the body. The study is divided into two parts Part 1 focuses on adults with obesity without T2DM, and Part 2 includes adults with obesity both with and without T2DM, testing ARO-ALK7 alone or combined with tirzepatide. Participants receive either single or multiple doses of ARO-ALK7 or matching placebo injections. In Part 2, some participants also receive weekly tirzepatide starting from Day 15 through Day 253. The doses of ARO-ALK7 are escalated to explore different levels of the drug. The study compares ARO-ALK7 alone, placebo, ARO-ALK7 combined with tirzepatide, and placebo combined with tirzepatide to assess their effects. During the study, participants are monitored for treatment-emergent adverse events until Day 253. Researchers collect detailed information on how the drug moves and acts in the body, especially during Part 1. Participants will have scheduled visits to receive treatments and undergo safety and effectiveness assessments. The total study duration covers up to about 8 and a half months, including dosing and follow-up, to fully evaluate the drugs impact and safety profile.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
8 locations
R

Actively Recruiting

Researchers are conducting a first-in-human, multi-center trial to study the effects of SRP-1005 in adults diagnosed with Huntingtons disease HD. This phase 1 study aims to evaluate the treatments safety and how the body processes SRP-1005, a drug administered by subcutaneous injection. The trial involves participants at specific stages of HD to better understand the impact of this investigational medication. Participants are randomly assigned to one of four groups receiving different doses of SRP-1005 or a placebo. All treatments are given by subcutaneous injection, with the study designed to carefully monitor each dose level. This randomized, double-blind, placebo-controlled trial includes dose escalation to assess safety and the drugs behavior at various concentrations. During the study, participants will undergo regular assessments to monitor adverse events and measure SRP-1005 levels in plasma, urine, and cerebrospinal fluid. The trial includes lumbar punctures and MRI scans as part of safety and feasibility evaluations. The main focus is on tracking any treatment-related side effects through week 24, with additional monitoring of drug concentration up to day 17 and cerebrospinal fluid levels through week 24. Participants are expected to be involved for about six months, including safety follow-up.

Age: 21Years - 70YearsAll GendersPhase 1
5 locations
F

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, pharmacokinetics how the drug moves through the body, and pharmacodynamics the drugs effects on the body of GRT7041 in healthy adult men and women who are not capable of childbearing. This Phase 1 trial aims to better understand how GRT7041 behaves in the body and its safety profile. The study is sponsored by Grnenthal GmbH and includes healthy volunteers aged 18 to 60 years. The trial has two parts. Part 1 involves single ascending doses SAD of GRT7041 in up to five groups, including adult males and women of non-childbearing potential, with dosing mainly under fasting conditions except for one group assessing the effect of food on drug absorption. Part 2 involves multiple ascending doses MAD given once daily for 14 days to adult males only, also under fasting conditions. The study also examines how GRT7041 interacts with another drug called midazolam in Part 2. Participants will undergo a screening visit, stay in the study facility during treatment periods, and attend follow-up or end-of-trial visits. Researchers will monitor adverse events, conduct physical exams, ECGs, vital signs, laboratory tests, and measure drug levels in the blood over time. The total duration for participants is up to approximately 6 to 8 weeks for Part 1 and up to 7 weeks for Part 2, including treatment and observation periods to evaluate safety and drug behavior in the body.

Age: 18Years - 60YearsAll GendersPhase 1
1 location
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating CTX310, a lipid nanoparticle formulation of CRISPR-Guide RNA-Cas9 nuclease, in adults aged 18 to 75 years with refractory dyslipidemias. This phase 1, open-label, multicenter trial aims to assess the safety and tolerability of CTX310 for in vivo editing of the ANGPTL3 gene in participants whose lipid disorders are resistant to available treatments. The study focuses on individuals with persistent dyslipidemias, including various types of hypercholesterolemia and hypertriglyceridemia. Participants will receive CTX310 as an intravenous infusion, with doses increasing over time to evaluate safety and tolerability. The trial is single-group and open-label, meaning all participants receive the investigational drug without a placebo group. The dosing and infusion schedules are designed to monitor how the treatment is processed and its effects on lipid levels. This study represents the first human trial of this CRISPR-based therapy. During the study, participants will be closely monitored through various assessments including safety evaluations, pharmacokinetics, pharmacodynamic responses, and measures of lipid levels over 12 months following the infusion. Researchers will track any adverse effects and the drugs impact on the participants dyslipidemia. Safety data will be collected from the time of infusion up to 12 months to fully understand CTX310s profile in this patient group.

Age: 18Years - 75YearsAll GendersPhase 1
17 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations

1-10 of 122

1